The share of expenditure on medicines as part of the total out-of-pocket (OOP) expenditure on healthcare services has been reported to be much higher in India than in other countries. This study was conducted to ascertain the extent of this share of medicine expenditure using a novel methodology.
In order to understand how the roll-out of the Ayushman Bharat- Health and Wellness Centre programme takes place in Punjab, a support centre for testing innovations and generating learnings for scaling up of the programme, was established in the Department of Community Medicine and School of Public Health, PGIMER, Chandigarh in collaboration with the National Health Systems Resource Centre, New Delhi and the State Health Society, Punjab. The ?Innovation and Learning 2022 New Delhi Centre for comprehensive primary healthcare (CPHC-ILC)? supports the state implementation team for change management through technical inputs on the components of CPHC, training and capacity building, and works closely at the ground level to address implementation issues in service delivery of CPHC.
This is the largest 5-level version EQ-5D (EQ-5D-5L) valuation study conducted so far/worldwide and the first preference-based valuation study in South Asia. The study was conducted using a novel design in around 3500 respondents across six states of India. By developing the EQ-5D-5L value set for India, this study fills the long-existing evidence gap in the field of health technology assessment (HTA) in India. The value set generated as a part of this study will help to correctly assess the quality-adjusted life-years (QALYs) in Indian studies.
Online courses in health economics are envisaged to promulgate the principles of basic health economics and economic evaluation for health technology assessment (HTA). These courses are being delivered with the ?Support to Conduct Online Courses in Basic Health Economics and Economic Evaluation for Health Technology Assessment? by the HRD Scheme of the Department of Health Research. The online course in basic health economics is of three months duration while the advanced course is of five months duration. Each course comprises six modules that cover topics pertinent to sensitise policymakers, program implementers, researchers, academicians, clinicians, and other health-related professionals. These users are from varied educational and professional backgrounds ranging from researchers and clinicians to top-level policy & decision-makers. These courses orient the audience towards the dynamics behind resource allocation decisions using economic evidence as the mainstay. The salient feature is enabling this understanding to be contextualised to the Indian health system.
World Health Organization has prequalified the use of typhoid conjugate vaccine (TCV) in children over six months of age in typhoid endemic countries. The present study assessed the cost-effectiveness of introducing TCV separately for urban and rural areas of India. From a societal perspective, introduction of TCV is a cost saving strategy in urban India. Further, due to low incidence of typhoid infection, introduction of TCV is not cost-effective in rural settings of India
The ?Cost of Health Services in India (CHSI)? is the first large scale multi-site facility costing study to incorporate evidence from a national sample of both private and public sectors at different levels of the health system in India. A total of 38 public (11 tertiary care and 27 secondary care) and 16 private hospitals were sampled from 11 states of India. From the sampled facilities, a total of 327 specialties were included, with 48, 79 and 200 specialties covered in tertiary, private and district hospitals respectively. A mixed methodology consisting of both bottom-up and top-down costing was used for data collection.
Globally, 16 billion injections are administered each year of which 95% are for curative care. India contributes 25?30% of the global injection load. Over 63% of these injections are reportedly unsafe or deemed unnecessary. The objective of the current study was to assess the incremental cost per quality-adjusted life-year (QALY) gained with the introduction of safety-engineered syringes (SES) as compared to disposable syringes for therapeutic care in India. The study findings revealed that RUP syringes are estimated to be cost-effective in the Indian context. SIP and RUP?+?SIP syringes are not cost-effective at the current unit prices. Efforts should be made to bring down the price of SES to improve its cost-effectiveness